Caligan Partners LP Buys 412,347 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Caligan Partners LP increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,995,932 shares of the biotechnology company's stock after purchasing an additional 412,347 shares during the period. BioCryst Pharmaceuticals makes up about 6.0% of Caligan Partners LP's portfolio, making the stock its 6th biggest holding. Caligan Partners LP owned approximately 1.45% of BioCryst Pharmaceuticals worth $22,529,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BCRX. Freestone Grove Partners LP bought a new position in BioCryst Pharmaceuticals during the 4th quarter worth $228,000. Schonfeld Strategic Advisors LLC grew its holdings in shares of BioCryst Pharmaceuticals by 27.3% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 217,740 shares of the biotechnology company's stock worth $1,637,000 after purchasing an additional 46,650 shares in the last quarter. AQR Capital Management LLC increased its position in shares of BioCryst Pharmaceuticals by 6.6% in the fourth quarter. AQR Capital Management LLC now owns 839,274 shares of the biotechnology company's stock worth $6,311,000 after purchasing an additional 52,047 shares during the period. Northern Trust Corp raised its stake in BioCryst Pharmaceuticals by 7.7% in the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock valued at $15,077,000 after purchasing an additional 143,986 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $748,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded up $2.10 on Monday, hitting $11.03. The stock had a trading volume of 24,784,357 shares, compared to its average volume of 2,916,168. The stock has a 50 day moving average of $7.69 and a 200 day moving average of $7.80. The firm has a market capitalization of $2.31 billion, a P/E ratio of -18.08 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.75 and a twelve month high of $11.48.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.27. During the same period last year, the business earned ($0.17) earnings per share. The firm's revenue was up 56.8% compared to the same quarter last year. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on BCRX. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price for the company. Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 10th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Wedbush assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.13.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.